# Section 3 (Part A): Scientific Origins & Preclinical Basis *Idea generation → basic research → preclinical proof-of-concept, per program. Citations refer to the verified reference library (Appendix B). This section reconstructs **where each idea came from, who had it, and what animal/ex-vivo evidence justified moving into humans.*** --- ## The shared intellectual lineage Every program in this landscape descends from a single immunological premise: that the immune system can be taught to *tolerate* a specific antigen without being globally suppressed. This is the distinction between **antigen-specific immunotherapy** (re-educate only the disease-driving clones) and conventional immunosuppression (blunt the whole system). The founding observations came from three streams: 1. **Oral/mucosal tolerance biology (1900s–1990s)** — the observation that antigen delivered by tolerogenic routes (oral, portal-venous, apoptotic-cell mimicry) induces regulatory rather than effector responses. This is the conceptual parent of the celiac liver-targeting and nanoparticle programs. 2. **Altered peptide ligand / peptide-tolerance work (1990s–2000s)** — that soluble peptide delivered without danger signals anergizes or deletes cognate T cells and can expand regulatory subsets. Parent of Nexvax2, ATX-MS-1467, the proinsulin-peptide programs. 3. **Regulatory-T-cell and co-receptor biology** — that modulating the T-cell receptor complex (CD3) or presenting peptide-MHC in a tolerogenic geometry can convert pathogenic clones into regulatory ones. Parent of teplizumab (CD3) and the Navacim pMHC-nanoparticle platform. The programs diverge on **how antigen specificity is achieved**: teplizumab achieves none (it is pan-T-cell) and is included as the approved *precedent*; the peptide vaccines carry the epitope directly; the nanoparticle and liver-targeting platforms deliver antigen to a tolerogenic anatomical niche; and Navacim uniquely presents the peptide *already loaded on MHC*, the truest structural analog of a pMHC vaccine. --- ## 3.1 Tzield / teplizumab (Type 1 diabetes) — the approved precedent **Idea generation.** Teplizumab began not as a diabetes drug but as a tool to probe the role of T cells in autoimmunity. Jeffrey Bluestone (UCSF) engineered an Fc-receptor-non-binding ("Ala-Ala") humanized version of the OKT3 anti-CD3 antibody to deliver a partial, non-mitogenic TCR signal — the goal being to modulate rather than deplete T cells. Kevan Herold (then Columbia, later Yale) carried it into type 1 diabetes on the hypothesis that partial CD3 engagement would preferentially disable activated autoreactive effector T cells while sparing and even expanding regulatory populations. **Basic research.** The mechanistic package that justified human trials showed that Fc-non-binding anti-CD3: (i) induces a state of partial exhaustion/anergy in activated CD8 effectors (later characterized by TIGIT/KLRG1 exhaustion signatures); (ii) spares and relatively expands Foxp3+ and TR1 regulatory cells; and (iii) does so transiently, avoiding the cytokine-release toxicity of the parent mitogenic OKT3. Herold's group had shown as early as 1992 that non-activating anti-CD3 could prevent diabetes in the NOD mouse [Herold 1992, referenced within Herold2002]. **Preclinical → first-in-human bridge.** The NOD-mouse prevention and reversal data plus the engineered safety profile supported a direct move into new-onset human T1D. The first pivotal human readout [Herold2002, NEJM] showed a single 14-day course preserved C-peptide (endogenous insulin production) at one year in new-onset patients — the observation that seeded two decades of development. **Key references:** Herold2002 (first RCT), Keymeulen2005 (parallel anti-CD3 otelixizumab confirmation), Herold2013_AbATE (durable responders), and the at-risk prevention hypothesis that led to TN-10. --- ## 3.2 Nexvax2 (celiac disease) — the flagship epitope vaccine **Idea generation.** Nexvax2's intellectual core is arguably the most rigorous antigen-mapping effort in the field. Bob Anderson and Jason Tye-Din (Walter and Eliza Hall Institute, Melbourne) reasoned that because celiac disease is uniquely tractable — a *known* antigen (gluten), a *known* restriction element (HLA-DQ2.5), and a *measurable* T-cell response — one could define the exact set of immunodominant peptides driving disease and deliver precisely those to induce tolerance. **Basic research.** In a landmark study [TyeDin2010, Sci Transl Med] the group performed comprehensive, quantitative mapping of gluten T-cell epitopes in a large cohort of HLA-DQ2.5 celiac patients undergoing gluten challenge. They showed that the anti-gluten T-cell response, though theoretically vast, is dominated by a small hierarchy — three peptides (from α-, ω-, and hordein gliadins) account for the majority of the pathogenic DQ2.5-restricted response. This reductionism is what made a defined three-peptide vaccine conceivable. **Preclinical.** HLA-DQ2.5 transgenic mouse models and *ex vivo* human T-cell assays demonstrated that repeated exposure to these peptides in a non-immunogenic (intradermal, escalating-dose) regimen could shift the response toward anergy/tolerance rather than priming. The clinical-development company ImmusanT (Boston; Leslie Williams CEO, Anderson CSO) was formed to translate this. **Key references:** TyeDin2010 (epitope hierarchy — the scientific basis), Goel2017 (Phase 1 dosing), Truitt2019 (Phase 1b escalation). --- ## 3.3 TAK-101 / TIMP-GLIA (celiac) — the tolerogenic nanoparticle **Idea generation.** TAK-101 comes from Stephen Miller's laboratory (Northwestern) and the observation, decades in the making, that antigen coupled to apoptotic cells or apoptotic-cell-mimicking particles induces robust tolerance — the immune system reads the particle as "safe debris" and mounts a regulatory rather than inflammatory response. **Basic research & preclinical.** The pivotal platform paper [Getts2012, Nat Biotechnol] showed that biodegradable PLGA microparticles carrying encephalitogenic peptides, delivered intravenously, induced antigen-specific T-cell tolerance and prevented/treated experimental autoimmune encephalomyelitis (EAE, the MS model). Uptake by MARCO+ splenic/hepatic macrophages in the absence of costimulation was the mechanistic key. Cour Pharmaceuticals licensed the platform; for celiac, whole gliadin was encapsulated (TIMP-GLIA), and mouse and humanized models showed suppression of gliadin-specific responses. Takeda partnered the celiac asset as TAK-101. **Key references:** Getts2012 (platform PoC), Kelly2021 (Phase 2a translation). --- ## 3.4 KAN-101 (celiac) — liver-targeted glycan tolerance **Idea generation.** Anokion (Lausanne/Boston; spun from Jeffrey Hubbell and Stephan Kontos's work at EPFL/Chicago) built on the biology that the liver is a default tolerogenic organ: antigens delivered to hepatic antigen-presenting cells (via the asialoglycoprotein receptor, ASGPR) preferentially induce regulatory responses and clonal deletion. **Basic research & preclinical.** The founding technology conjugates antigen to glycan/erythrocyte-binding moieties that route it to the liver. Preclinical work showed antigen-specific deletion of cognate CD4/CD8 cells and Treg induction. KAN-101 delivers a deamidated gliadin peptide construct designed for hepatic tolerance. FDA Fast Track designation followed early clinical safety. **Key references:** (platform) Hubbell/Kontos liver-tolerance work; clinical readouts covered in Part B. --- ## 3.5 TPM502 / Topas Therapeutics (celiac) **Idea generation & science.** Topas (Hamburg) uses a nanoparticle platform that also exploits liver-resident APCs, conjugating peptide cargo to a carrier that concentrates in the liver. TPM502 carries a set of gluten peptides. The mechanistic thesis mirrors KAN-101 (hepatic tolerance) but via a distinct nanoparticle chemistry. Program is earlier-stage; preclinical package centered on antigen-specific Treg induction and reduced effector responses in HLA transgenic/humanized systems. --- ## 3.6 GAD-alum / Diamyd (Type 1 diabetes) — antigen + adjuvant **Idea generation.** GAD65 (glutamic acid decarboxylase) is a major autoantigen in T1D — anti-GAD antibodies are a diagnostic hallmark. The hypothesis (Diamyd Medical, Sweden; long associated with Johnny Ludvigsson, Linköping) was that administering recombinant GAD65 formulated in alum, a Th2-skewing adjuvant, would induce a regulatory/deviated response and preserve residual beta-cell function in recent-onset patients. **Basic research & preclinical.** Alum-formulated autoantigen had shown immune deviation toward Th2/regulatory phenotypes in rodent models. Early-phase human work suggested preservation of C-peptide in a subset, motivating a large Phase 3. **Key references:** Ludvigsson2012 (Phase 3), Ludvigsson2021 (DIAGNODE-2 intralymphatic + the HLA responder-subgroup pivot). --- ## 3.7 Navacims / Parvus Therapeutics (T1D & autoimmunity) — the true pMHC platform **Idea generation.** This is the platform most structurally analogous to a pMHC vaccine. Pere Santamaria (University of Calgary) asked whether nanoparticles densely coated with disease-relevant **peptide-MHC class II complexes** could directly engage cognate autoreactive CD4 T cells and re-program them — not delete them, but convert them into a regulatory (TR1-like) phenotype that then suppresses the broader autoimmune response at the target tissue. **Basic research & preclinical.** The landmark paper [ClementeCasares2016, Nature] demonstrated that pMHC-II-coated nanoparticles ("Navacims") expanded antigen-experienced, disease-relevant CD4 T cells into TR1 cells that formed regulatory networks and reversed disease across *multiple* mouse models (T1D, EAE, arthritis, and a humanized model). A follow-on [Singha2017, Nat Nanotechnol] extended the mechanism and design rules (epitope density, MHC allele, nanoparticle size). Parvus Therapeutics was founded to commercialize the platform. **Why it matters for EoE.** Navacim is the proof that a *peptide-MHC* presentation, not just free peptide, can induce durable antigen-specific regulation *in vivo* — the mechanistic north star for a pMHC EoE vaccine. **Key references:** ClementeCasares2016 (Nature PoC), Singha2017 (design rules), Serra2019 (field review). --- ## 3.8 Proinsulin peptide immunotherapy / MonoPepT1De & MultiPepT1De (T1D) **Idea generation.** Mark Peakman's group (King's College London) pursued the most direct human translation of peptide-tolerance biology in T1D: administer a single immunodominant proinsulin peptide (C19-A3, HLA-DR4-restricted) intradermally to induce regulation. **Basic research & preclinical.** Extensive human *ex vivo* work defined the proinsulin epitope and the regulatory (IL-10+) response signature that a tolerogenic dose should induce. Dose and interval were modeled to favor regulation over priming. **Key references:** AlhadjAli2017 (MonoPepT1De Phase 1a — safety and mechanistic tolerance readouts; the first placebo-controlled peptide-immunotherapy safety demonstration in new-onset T1D). --- ## 3.9 ATX-MS-1467 (Multiple sclerosis) **Idea generation & science.** Apitope (UK/Belgium; David Wraith's tolerogenic "apitope" — antigen-processing-independent epitope — concept) designed a mixture of four myelin basic protein (MBP) peptides selected to bind MHC and engage autoreactive T cells in a tolerogenic manner. Preclinical basis rested on the altered-peptide-ligand and soluble-peptide tolerance literature in EAE. Merck KGaA partnered the asset. **Key references:** Chataway2018 (Phase 2, MRI lesion endpoints). --- ## 3.10 DEN-181 (RA) and adjacent context **Idea generation & science.** Ranjeny Thomas (University of Queensland) developed a liposomal formulation co-delivering a citrullinated collagen II peptide with an NF-κB inhibitor (calcitriol/Bay11-7082 lineage) to program dendritic cells toward a tolerogenic state — antigen-specific tolerance for rheumatoid arthritis. Included as adjacent context for the platform diversity it represents (tolerogenic-DC targeting) rather than a full commercial dossier. --- ## Synthesis: what the origins tell us for EoE - **The best programs started from a defined antigen and a measurable T-cell readout** (Nexvax2's epitope map; GAD's autoantibody; proinsulin). EoE's challenge is that the driving antigen(s) — food allergens (milk, wheat, egg, soy) — are *plural and patient-variable*, unlike celiac's single gluten system. This is the single most important scientific-origin lesson. - **pMHC presentation (Navacim) is validated in vivo** but has not yet cleared the clinic — the whitespace an EoE pMHC program would enter. - **Delivery niche matters as much as the peptide** (liver targeting, nanoparticle apoptotic-mimicry). An EoE program must choose its tolerogenic route deliberately.